Feed CYTK
CY

Cytokinetics

CYTK · NASDAQ

$67.56 -1.40% (-$0.96)
1M -12.36%
Market Cap $8.41B
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/S 118.47x
P/E N/A
P/FFO N/A
Growth
8 /100
Declining
Rev. growth 2.36%
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Gross margin 84.97%
FCF margin 818.37%
Net margin 1,259.87%
Quality
1 /100
Poor
ROIC 39.33%
Asset turnover 0.04x
ROA 46.45%
Debt
43 /100
Moderate
Current ratio 6.66x
Int. coverage -6.68x
Debt/Equity N/A
Stability
40 /100
Moderate
Beta 0.36x
Profitable years 0
Rev. volatility 234.30%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre CYTK
Online

Despre companie

Cytokinetics, Incorporated is an American biotechnology company specializing in the development of therapeutic approaches aimed at improving muscle function in patients with heart and muscle diseases. The company develops innovative drug candidates targeting the regulation of muscle proteins, which can help treat conditions such as heart failure, amyotrophic lateral sclerosis (ALS), and other muscle disorders. Cytokinetics focuses on providing new treatment options for patients for whom current therapies are insufficiently effective.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert I. Blum

Employees

673

Headquarters

South San Francisco

Evenimente viitoare

04 NOV.

Earnings

Upcoming earnings report

43d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.